ASX:CSL - CSL Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CSL Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$310.70 +3.51 (+1.14 %) (As of 01/26/2020 05:54 AM ET) Add Compare Today's RangeA$308.02Now: A$310.70▼A$313.5950-Day RangeA$275.04MA: A$286.90▼A$310.7052-Week RangeA$184.00Now: A$310.70▼A$299.90Volume1.00 million shsAverage Volume900,202 shsMarket Capitalization$141.01 billionP/E Ratio73.52Dividend Yield0.99%BetaN/A ProfileAdvanced ChartDividendEarningsInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. Read More… Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:CSL Previous Symbol CUSIPN/A CIKN/A Webhttp://www.csl.com.au/ Phone+61-3-93891911Debt Debt-to-Equity Ratio88.79 Current Ratio2.53 Quick Ratio1.09Price-To-Earnings Trailing P/E Ratio73.52 Forward P/E Ratio63.67 P/E Growth2.43 Sales & Book Value Annual Sales$8.54 billion Price / Sales16.51 Cash FlowA$1.52 per share Price / Cash Flow204.06 Book ValueA$11.59 per share Price / Book26.81Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares453,854,016Market Cap$141.01 billion Next Earnings Date2/12/2020 (Estimated) OptionableOptionable Receive CSL News and Ratings via Email Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter. CSL (ASX:CSL) Frequently Asked Questions What is CSL's stock symbol? CSL trades on the ASX under the ticker symbol "CSL." How often does CSL pay dividends? What is the dividend yield for CSL? CSL declared a Final dividend on Friday, August 16th. Investors of record on Friday, October 11th will be given a dividend of 1.478 per share on Friday, October 11th. This represents a yield of 0.65%. The ex-dividend date of this dividend is Tuesday, September 10th. View CSL's Dividend History. How were CSL's earnings last quarter? CSL Limited (ASX:CSL) posted its quarterly earnings results on Wednesday, August, 14th. The company reported $4.24 earnings per share for the quarter, topping the Zacks' consensus estimate of $4.22 by $0.01. View CSL's Earnings History. When is CSL's next earnings date? CSL is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for CSL. Has CSL been receiving favorable news coverage? Headlines about CSL stock have trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CSL earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for CSL. Who are some of CSL's key competitors? Some companies that are related to CSL include MorphoSys (MOR), MorphoSys (MOR), Cronos Group (CRON), BTG (BTG), Abcam (ABC), Kodiak Sciences (KOD), Vir Biotechnology (VIR), Genus (GNS), Polynovo (PNV), Mesoblast (MSB), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Immutep (IMM), Paradigm Biopharmaceuticals (PAR) and BELLUS Health (BLU). What other stocks do shareholders of CSL own? Based on aggregate information from My MarketBeat watchlists, some companies that other CSL investors own include Commonwealth Bank of Australia (CBA), Woodside Petroleum (WPL), BHP Group (BHP), REA Group (REA), RESMED/IDR UNRESTR (RMD), Appen (APX), Afterpay Touch Group (APT), Altium (ALU), Blackmores (BKL) and Cochlear (COH). Who are CSL's key executives? CSL's management team includes the folowing people: Mr. Paul R. Perreault, MD, CEO & Exec. Director (Age 62)Mr. David Mark Lamont ACA, BCom, Chief Financial Officer (Age 53)Dr. Robert Andrew Cuthbertson, Chief Scientific Officer & Director of R&D and Director (Age 64)Mr. Gregory Boss BS(Hons), J.D., Exec. VP of Legal & Group Gen. Counsel (Age 58)Ms. Elizabeth Walker, Exec. VP & Chief HR Officer (Age 49) What is CSL's stock price today? One share of CSL stock can currently be purchased for approximately A$310.70. How big of a company is CSL? CSL has a market capitalization of $141.01 billion and generates $8.54 billion in revenue each year. View Additional Information About CSL. What is CSL's official website? The official website for CSL is http://www.csl.com.au/. How can I contact CSL? CSL's mailing address is 45 Poplar Road,, Parkville, MELBOURNE, VIC 3052, Australia. The company can be reached via phone at +61-3-93891911. MarketBeat Community Rating for CSL (ASX CSL)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 195 (Vote Outperform)Underperform Votes: 135 (Vote Underperform)Total Votes: 330MarketBeat's community ratings are surveys of what our community members think about CSL and other stocks. Vote "Outperform" if you believe CSL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: Float
